Immunotherapy with cat- and dog-dander extracts. IV. Effects of 2 years of treatment.
Thirty-five patients (20 children and 15 adults) with animal-dander asthma completed 2 years of immunotherapy with partly purified and standardized cat- or dog-danger extracts. The first year of the study was performed double-blind with a placebo-treated control group. These 15 patients were transferred to active treatment for a second year. All patients were followed by use of the skin prick test (SPT), allergen and histamine bronchial challenges, and tests for allergen-specific IgE, IgG1, and IgG4 levels. In the group treated with active extracts for 2 years (group A), the previously reported decrease in bronchial responsiveness to cat extract (p less than 0.001) and histamine (p less than 0.01) was even more pronounced after the second year. After 1 year of active treatment in the original placebo group (group B), a significant decrease in the bronchial responsiveness to cat extract was noted (p less than 0.001). The responsiveness to histamine was decreased only in the patients treated with cat-dander extracts (p less than 0.05). A significant decrease in the SPT (p less than 0.001) and an increase in the allergen-specific IgE (p less than 0.001) and IgG4 (p less than 0.001) was also noted in patients (group B) treated with cat-dander extracts. The side effects in the two groups (A and B) were negligible, except for some systemic side effects, especially among the children during the initial phase of immunotherapy. The symptoms were mild and responded promptly to treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
Lilja
G
G
University Hospital of Sachs, Stockholm, Sweden.
Sundin
B
B
Graff-Lonnevig
V
V
Hedlin
G
G
Heilborn
H
H
Norrlind
K
K
Pegelow
K O
KO
Løwenstein
H
H
D000293:Adolescent; D000328:Adult; D000485:Allergens / Q000008:administration & dosage* / Q000633:toxicity; D000818:Animals; D001985:Bronchial Provocation Tests; D002415:Cats; D002648:Child; D003888:Desensitization, Immunologic / Q000379:methods; D004285:Dogs; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006197:Hair / Q000276:immunology*; D006632:Histamine; D006801:Humans; D007073:Immunoglobulin E / Q000378:metabolism; D007074:Immunoglobulin G / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate; D011852:Radioallergosorbent Test; D012882:Skin Tests
D000485:Allergens; D007074:Immunoglobulin G; D007073:Immunoglobulin E; D006632:Histamine